

ATRIX LABORATORIES INC

Form 425

August 05, 2004

Filed by Atrix Laboratories, Inc.
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934

Subject Company: Atrix Laboratories, Inc.
Commission File No. 000-18231

The following is a transcript of the conference call held on August 4, 2004 at 11:00 a.m. Eastern time regarding Atrix Laboratories, Inc.'s second quarter financial results.

ATRIX
Second Quarter Financial Results

August 4, 2004
10:00 am CT

Conference Coordinator: Good afternoon ladies and gentlemen, and welcome to the Atrix's Second Quarter Financial Results Conference Call.

At this time, all lines are on a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will be given at that time.

And now, I'll turn the program over to Jennifer Geraci, Investor Relations Representative.

Please go ahead, Ma'am.

Jennifer Geraci: Thank you.

Good morning and welcome to Atrix's Second Quarter Conference Call.

The earnings press release was distributed this morning as well as furnished on a Form 8K to provide access to the widest possible audience. If you did not receive a copy, these documents are available on the company's Web site at www.atrirlabs.com in the Press Release section.

ATRIX
Second Quarter Financial Results
Moderator: Jennifer Geraci
08-04-04/10:00 am CT
Page 2

Joining me today are Mr. David Bethune, Atrix's Chairman and Chief Executive Officer, Mr. Michael Duncan, Vice President and General Manager, Dr. Stephen Warren, Vice President of Research and Development and Chief Scientific Officer, and Mr. Greg Gould, Atrix's Chief Financial Officer.

Before I turn the call over to Mr. Bethune, I'd like to review the company's Safe Harbor Guidance.

At this time, management would like me to inform you that certain statements made during this conference call, which are not historical, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

While Atrix believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Factors and risks that could cause actual results to differ materially from those expressed or implied are detailed in today's press release and from time to time in the company's filings with the SEC.

The company does not undertake a duty to update any forward-looking statements and the company assumes no obligation to update or revise any of its forward-looking statements even if the experience or future changes shows that the indicated results or events will not be realized.

In connection with the QLT's proposed merger with the Atrix Laboratories, Inc., QLT has filed with the SEC a registration statement on Form S4 containing a joint proxy statement perspective and other relevant materials.

Investors and security holders of QLT and Atrix are urged to read the preliminary joint proxy statement perspectives regarding the transaction and the definitive joint proxy statement perspective when it becomes available, as well as other relevant materials because they will contain important information about QLT, Atrix, and the transaction.

The preliminary joint proxy statement perspective on file with the SEC and the definitive joint proxy statement perspective and other relevant materials, when they become available, and any other documents filed by QLT or Atrix with the SEC may be obtained free of charge at the SEC's Web site at sec.gov.

The definitive joint proxy statement perspective and other relevant materials, when they become available, will be mailed to stockholders of QLT and Atrix in advance to the special meetings to consider the transaction.

In addition, investors and security holders may obtain free copies of the documents, when they are available, filed with the SEC by QLT by directing a request to QLT Inc., Attention: Investor Relations, 887 Great Northern Way, Vancouver, BC, Canada V5T 4T5.

Investors and security holders may obtain free copies of the documents filed with the SEC by Atrix by contacting Atrix Laboratories Inc., Attention: Investor Relations, 2579 Midpoint Drive, Fort Collins, Colorado 80525.

QLT, Atrix and their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from the stockholders of QLT and Atrix in favor of the transaction.

Information about the executive officers and directors of QLT and their ownership of QLT common shares is set forth in the proxy statement for QLT's 2004 annual meeting of shareholders which was filed by the SEC with the SEC as Exhibit 99.1 to Form 10K-A on April 28, 2004.

Information about the executive officers and directors of Atrix and their ownership of Atrix common stock is set forth in the proxy statement for Atrix's 2004 Annual Meeting of Stockholders which was filed with the SEC on April 5, 2004.

Investors and security holders may obtain more detailed information regarding the direct and indirect interest of QLT, Atrix, and their respective executive officers and directors, and the transaction by reading the definitive joint proxy statement perspective regarding the transaction when it becomes available.

At this time, I will turn the call over to Mr. David Bethune.

David?

David Bethune:

Thank you, Jennifer.

It's a pleasure to speak to you today about Atrix's second quarter business results.

As most of you know, Atrix made a fundamental strategic decision this quarter. In June, Atrix and QLT announced the decision to merge the two companies and begin the effort to build a world-class leading profitable biopharmaceutical company.

We are currently going through an SEC review process on this transaction. The closing date on this transaction is contingent upon this review process.

Let me reiterate why I think these two companies is good for the Atrix shareholder. The Atrix-QLT merger represents an excellent opportunity for a number of reasons.

It will create a company with a larger and growing revenue base of proprietary products, complementary product portfolios especially in dermatology and oncology; and manufacturing capabilities that together should enhance shareholder value.

QLT is a profitable biotechnology company with an excellent financial resources required to accelerate the development of Atrix pipeline. The combined company will allow Atrigel with our growing base of knowledge of this technology to be utilized to an even greater degree in solving drug delivery challenges throughout the industry.

Together, we can maximize the combined companies core technologies to develop novel products and ultimately achieve our goal of becoming a fully-integrated leading biopharmaceutical company.

As I indicated earlier, we share expertise in dermatology and in oncology product development. Additionally, starting ocular disease therapies may have utility with the Atrigel delivery system.

The combined company will help multiple near and long-term value drivers Visudyne, Eligard and several generic dermatology products which are currently on the market.

Atrix will also provide a strong group of product opportunities that includes unique Eligard six-month formulation, Atrisone, Octreotide MICRaS, Atrogel-Risperidone, and an obesity peptide, a topical (immuno-epicotic) agent, and several other dermatology products, all of which could become solid value drivers for the combined company.

We also see possibilities in what would be a truly differentiated sustain release drug delivery platform why systemic and topical application, and a potential delivery system for ocular disease therapies.

With the combined company having cash of approximately \$300 million at the closing of this transaction, free cash flow and a diverse source of revenue, the merger of Atrix and QLT creates a more powerful bio pharmaceutical company that has resources to grow its profits and invest in the Atrix pipeline of products.

I am pleased to report that the second quarter saw outstanding revenue growth for Atrix. This quarter, net sales and royalties increased to \$12 million, a 163% increase over the second quarter of 2003, mainly due to the sales of our Eligard and generic dermatology products.

Total revenue increased 53% to approximately 18.9 million due to, primarily, the sales and royalty revenue earned from the continued growth of Eligard products in the US and around the world, which total 9.9 million.

During this quarter, our operating expenses increased to \$18 million. Included in this increase were one-time expenses related to the QLT transaction of \$1.3 million and added production demand for Eligard launches in the second quarter in Germany and Mexico.

If Atrix had not incurred the QLT transaction expenses, the operating expenses would have been 16.7 million. Profit from operations were approximately \$877,000 which if we exclude the non-recurring expenses, Atrix would have had a profit from operations of 2.2 million, which is an increase over our first quarter of this year of 118%.

Net income applicable to common stock was \$830,000 or 4 cents per fully diluted share. If we exclude the non-recurring transaction expenses, we have net income applicable to common stock of 2.2 million or 10 cents per share fully diluted.

We are pleased with the growth of our Eligard products experience during this quarter. In the last several months, we have significantly expanded the availability of Eligard around the world.

Our sales growth was helped during the last quarter with the launch of Eligard in one and three-month products in Germany (by) MediGene, Yamanouchi. Also, in the second quarter, Atrix's Latin American (licensee) Tecnofarma International received marketing authorization from the Mexican regulatory authorities for the one and three-month Eligard products.

Right now, Tecnofarma is marketing Eligard in Mexico and Argentina, and marketing authorizations have been submitted for Peru, Brazil, Venezuela, Bolivia, Columbia, Chile, and other countries throughout that region.

Our North American marketing partner for Eligard, Sanofi-Synthelabo, has gained formulary approval in the Canadian Provinces of Quebec and now, Ontario, the two largest provinces in Canada for the one and three-month product. And I understand, about 70% of the total LHRH total market opportunity exists in those two provinces.

The six-month Eligard 45 milligram product continues this review through the FDA process offering another potential revenue growth opportunity. In July, Sanofi-Synthelabo, Canada filed for marketing authorizations with the Canadian regulatory authorities for the six-month Eligard product. The demand for longer release products is excellent, and the Eligard 45 milligram products would be the first of their kind in these markets.

We also (made strive) in our generic dermatology business this quarter. In May, we announced that the FDA approved our fluticasone propionate cream, our first generic Fluticasone Cream to be approved by the FDA.

Sandoz, our marketing partner for this product launched Fluticasone Cream shortly after its branded counterpart Cutivate (went off) patent in May.

During the quarter, we have recognized 1.6 million in shipment and profit sharing for the Fluticasone Cream and the Erythromycin/Benzoyl Peroxide products combined.

Additionally, Atrix received tentative approval for Mometasone Cream in July. This product is an AB-rated generic to the topical Elocon cream which have a patent that expires in 2007.

This quarter, we also entered into agreement with one of the largest pharmacy retail chain companies to manufacture a group of Atrix's branded, unique proprietary topical products scheduled to be launched starting in August.

We are very excited about this partnership, and it is another opportunity to utilize our patented drug delivery technologies, as well as our formulation, developmental and manufacturing expertise.

With the generic products on the market bringing in revenues and more products moving forward in the pipeline, we are confident of a viable future for our dermatology business as we move into the second half of this year.

We posted a higher cost of sales this quarter due to Eligard launches in Germany and Australia and the shipment of more generic derma products which included Erythromycin/Benzoyl Peroxide and Fluticasone Cream.

We also recognized a charge for a lost batch of Eligard that totaled approximately \$350,000 which our current (factory) manufacturers did not manufacture according to our specifications.

In an effort to gain more total control of our manufacturing process and avoid these situations in the future, Atrix filed a prior approval supplement to the Eligard NDA this month to move the (lapillation) process of the Eligard products from the contract manufacturer to our Fort Collins manufacturing site, which will put the products under our total and direct control. This should help reduce the cost of all Atrigel products produced.

As many of you know, the facility was expanded during the past year and equipped with state-of-the art (lapillation) equipment in order to facilitate this change.

Test batches have been run and stability data generated showing (equivalency) and improved reliability to the process as compared to our contract manufacturer.

After successful inspection of the Atrix's facility by the FDA and review of the scientific data establishing (equivalency) and the improvement of process,

approval of this submission will bring full and complete control of the Eligard products to our site in Fort Collins.

We are excited to move Atrix and its pipeline into this new phase. With products currently on the market bringing in revenues and the means to enhance the gathering momentum of our pipeline, we look forward to a bright and profitable future.

Now, this concludes my remarks for the second quarter, and now, we would be happy to take any questions that you may have.

Any questions?

Conference Coordinator: Again, if you would like to ask a question, please press star and 1 on your touchtone phone.

To withdraw your question from the queue, please press the pound key.

To ask a question, please press and 1 on your touchtone phone.

And we'll take just a moment for any questions to register.

We'll take our first question from the site of Christine Charette, with Nesbitt Burns.

Please go ahead.

Christine Charette: Hi, thanks.

Just looking forward, how should we be thinking about your R&D revenue? Much of your revenue came from products who s who are fully developed now, for example, Atrisone, you finished the Phase 3, Eligard six-months is already been filed as you re already getting the first approval in Europe. So, I m wondering, how should we think about those revenues going forward.

David Bethune:

Well, I think, as I stated in my formal comments, we continue to get approval; we continue to see early successes especially in Germany and Australia, so the international segment of our Eligard business will continue to grow as we see it now.

We will have additional approvals coming forward in South America as well. The use of the product is increasing; while it is a tough competitive battle here in the United States, we re seeing growth continue there.

We are extremely excited about the Eligard six-month product. It is under review now. We expect a 12-month review while we receive we ve been fortunate to receive 10-month review and approvals for all three of the previous NDAs for Eligard.

They are it s no obligation that that 10-month review cycle will continue, so we could expect the approval by that for the six-month product and the 10 to 12-month period here coming up. So, we have that.

We also, as I indicated, have revenue continuing to grow with our generic dermatology business, and that will continue on as well. And a new source of revenue, that I mentioned, was the drug chain business that we recently acquired that will begin to come on stream shortly.

Christine Charette: Sorry, perhaps I didn't make myself clear. I was referring directly to R&D revenue, not overall revenue but R&D revenue.

David Bethune: Oh, the R&D revenue continues to grow and go forward, but there will be a reduction as we complete the massive study underway with Atrisone.

Atrisone is a very comprehensive and complex process. We reimburse a great majority of that by our partner Fujisawa, and that will be winding up as we get ready to file the NDA for Atrisone end of the third quarter of this year.

Christine Charette: So, we can expect those revenues to come down after this quarter basically, Q2?

David Bethune: Well, I don't think that they're going to come down drastically, but let me ask Greg Gould, our CFO to make some comments regarding this revenue expansion.

Gregory Gould: Yeah.

Right, now moving forward, we would most likely see our contract R&D revenue to go down slightly, but one thing with that, we are constantly going out talking to new companies who might want to use our services and, right there, could affect our R&D revenue in the future. But if we sign no more contract as of today, it would go down in the future.

Christine Charette: Okay.

Can you give us some idea of the size of that?

Gregory Gould: You know, we typically do not give specific guidance going forward, so...

Christine Charette: (Okay).

Gregory Gould: ...I would just say that it would go slightly down in the future.

David Bethune: Let me ask (Mike).

We have (Mike) Duncan, our Vice President and General Manager, who also is responsible for assisting in the development of business, development opportunities with other pharmaceutical companies, and we do have additional revenue sources of what you're calling a reimbursed R&D revenue coming in as well.

(Mike)?

Michael Duncan: Yes.

Just I'll just mention quick comments on this point again.

As you all, the generic dermatology products we have publicly disclosed before, that those are all 50% reimbursed. On the Atrisone product, the bulk of those expenses is the clinical trials and the filing of the NDA, but reimbursement support does continue through NDA approval.

On the six-month product, again, we're still receiving financial support of that, provide NDAs approved in that product's launch.

And then another big point I want to bring up is we do have several partnerships with major pharmaceutical companies where we are developing feasibility entities in our Atrigel system. The only two we have announced on

that is Pfizer and Aventis but we have deals with five of the Top 10 pharmaceutical companies that we have not disclosed as other partners yet.

So, R&D revenue will drop slightly, again, as Greg said, just because of the Atrisone NDA will be filed in the third quarter but the, you know, you're still going to see an R&D revenue line on to the future.

Christine Charette: Are you checking any potential revenue for the (areas of BMA) or.

Michael Duncan: No, (areas is a) you know, we've licensed the BMA technology to (areas) and the far as R&D on that, no, because they're going to take over the R&D efforts of that product. They will reimburse us for a while until the price technically transferred to them.

Christine Charette: Okay.

And can you give us some any color on Eligard sales in the US versus the rest of the world?

David Bethune: Well, Eligard in the US is going well. As I indicated earlier in my formal comments, the product is a challenging product; it's highly competitive here in the US. There's been price erosion. There's been some disruption there, but overall, we're moving the product forward in the US as well as around the world.

And the excitement is that we have a unique product here with Eligard six-month coming along very shortly, and we believe we'll be the only company there with that particular dosage form given what we have learned in the marketplace concerning the competitive products and (where it is) in its clinical trials program.

Christine Charette: Okay.

But can you give us some color of as your royalty, what roughly the split between the US and the rest of the world?

David Bethune: We have never given out royalties. We have (licensing) agreement with Sanofi. Since (they're now out) Sanofi advances I guess we would call it.

We have a (licensing) agreement which are requires us to this new keep confidential the royalty arrangement that we have with that company.

Christine Charette: Yeah, I understand that.

But can you give us roughly your revenues, what roughly how much of your revenues come from the US as opposed to the rest of the world?

David Bethune: I don't believe we've in the past broken out that.

Greg, so you might comment there.

Gregory Gould: Yeah, it's something we've never broke out in the past right now, so majority of our Eligard revenue, it does come from the US, so.

David Bethune: I think you're seeing though that it is it will be increasing as we.

Gregory Gould: Yeah.

David Bethune: ...file these initial shipments for these earlier approvals that we've received around the world to start increasing in terms of the overall percentage of the total.

Christine Charette: Okay.

So, let me post the question in another way. In order for us to forecast going forward sales in the rest of the world, can you give us some idea of your royalty in Q2? How much of that would probably in the rest of the world due to stocking as opposed to actual sales?

David Bethune: Well...

Christine Charette: (Most) of your extra (raft) revenue for Eligard with stocking.

David Bethune: It's in the initial supply for stocking of a product. As I indicated to you when you start selling a product, it's usually the result of the marketing survey to determine how much of the product would be of the demand and that would be initial supplies to stock the pipeline of the product.

Christine Charette: Can you give us an idea of how large that was?

David Bethune: All of these markets are new essentially. The German market came on board in May.

Man: In May.

David Bethune: So, you can't hardly give a history of how well the product is going until we see some experience there.

Man: (You see), Christine...

Christine Charette: Okay, thank you.

Conference Coordinator: Thank you.

Our next question comes from the site of (Ken McClay) with CIBC World Market.

Please go ahead.

(Ken McClay): Hi. Good morning, gentlemen.

David Bethune: Good morning.

Man: Good morning.

(Ken McClay): I was just wondering if you could provide some background information on the gross margin, the quarter seemed a little bit lower. And then also any broad comments you have in Eligard pricing in the US would be interesting.

David Bethune: Okay. I'll ask Greg to comment about that.

Gregory Gould: Yeah.

With our cost of goods sold it did go up this quarter, and the major driving factors of that were, Number 1, the additional products we shipped out for our launches in Germany and in some of the rest of the world, and also due to having a higher revenue from our generic products which have a higher cost of sales force compared to Eligard, and lastly, we did lose an Eligard batch at

one of our outside suppliers during the quarter, and also had one generic batch get lost here during the quarter which (accredited) into a little bit over 400,000.

And between those three factors, it did raise our cost of goods sold our cost of good of sales during the quarter and we would hope and expect that those would probably come down to a smaller percentage of total sales in the future.

(Ken McClay):

Great.

And on the Eligard pricing cut?

David Bethune:

I m sorry, on the Eligard?

(Ken McClay):

Pricing cut.

David Bethune:

Pricing cut.

Well, in the past we ve had some pricing pressures. And Sanofi as our marketing partner of the Eligard products in the US, and I believe it would be more focused for them to comment on pricing.

We do not control the pricing of Eligard products but we do anticipate that there would be some that there wouldn t be any significant erosion. In fact, our pricing that we recently saw for the CMS was lower than the advocated price that they were publishing in the Federal Government registrar, I suppose. So, our selling price was even lower than they had as a minimal price.

Is that correct, (Mike)?

Michael Duncan: That s correct.

Yeah, they recently published that CMS reimbursement price. Atrix is below that anyway or Sanofi is below that anyway so...

(Ken McClay): Uh-huh.

Michael Duncan: ...we re in good shape there, but as far as so right now everybody is in this six months, you know, as the CMS is six months average pricing. We saw some erosion in the first quarter but that kind of stabled out in the second and third because everybody return their prices in the CMS in October.

(Ken McClay): Uh-huh.

Michael Duncan: ...for the reimbursement to start in 05.

(Ken McClay): Okay.

So, you haven t seen any movement from that product otherwise?

Michael Duncan: No, we don t expect any significant movement in this.

(Ken McClay): Uh-huh.

Michael Duncan: ...next quarter either.

(Ken McClay): Okay, great.

And then you said about bringing the Eligard production in-house. I mean what kind of benefit would see the gross margin from the increased efficiencies there?

David Bethune

Well, I think that they're going to be improved and we at least...

(Ken McClay):

Uh-huh.

David Bethune

...we've invested a lot of money into their own (unintelligible), somewhat for our controls purposes but also for efficiency purposes.

(Mike), would you like to comment about that?

Michael Duncan:

Yeah, I mean, you know, obviously, and just to be fair too and to answer your question as directly as possible is that as you get the product (standing), you start making batches, you don't know you can only estimate what's your gross margin's improvement going to be.

(Ken McClay):

Uh-huh.

Michael Duncan:

...obviously, anticipate, you know, we would have done it that means we're going to improve our gross margins.

But even more so, they were going to increase our control or the process. I mean right now, you know, losing a batch is, you know, the straight loss for us and so we want to be able to control the quality of the product even more so, so we should be able to, you know, to reduce the numbers of loss batches and increase our margins.

I just honestly, nobody could tell you that really, we could just, you know, give you a guess until we get history on making, you know, many batches. You know, we can't really tell you what it's going to be honestly.

(Ken McClay): Okay, that's all right.

Thank you very much for the questions, guys.

David Bethune: Thank you.

Michael Duncan: Sure.

Conference Coordinator: Thank you.

Our next question comes from the site of Noelle Tune with Leerink Swann.

Please go ahead.

Noelle Tune: Good morning.

I believe last quarter you broke up gross Eligard sales for the quarter. Can you give us that number this time?

David Bethune: Yeah.

Greg Gould: Yeah, our gross Eligard sales, what we did internally was 9.9 million.

Noelle Tune: Is that your royalty or gross Eligard sales by Sanofi?

Greg Gould: Our gross by Sanofi, they said during our conference call that they did \$34 million during the first half of this year.

Noelle Tune: Great.

Thanks very much.

Conference Coordinator: Thank you.

Our next question comes from the site of (Jeffrey Perrin) with Perrin Financial.

Please go ahead.

(Jeffrey Perrin): Yes, I've got a question about the larger terms. We have been told that there's a penalty to pay if doesn't go through, but when you negotiated it, it was worth roughly 35-1/2 per share and now about 31.

Does the do the terms contain a floor value? I mean if QLT stock continues to drop, if there's some value below which there won't be a penalty if the shareholders or directors choose not to.

David Bethune: Well, and there's no penalty if the stockholders do not approve it.

Michael Duncan: It's really that simple.

David Bethune: Yeah.

(Jeffrey Perrin): So, that would only be if somebody else came in (and bid). It wouldn't apply to the shareholders, okay.

David Bethune: Yes, exactly.

(Jeffrey Perrin): Okay, thanks.

David Bethune: Yes, sir.

Conference Coordinator: Thank you.

Our next question comes from the site of (Harvey Kubitski) with Maloney Securities.

Please go ahead.

(Harvey Kubitski): Yes.

Just as curious as to why you would wanted to transfer the (beamer) rights that you ve just got you re going to have this extra money, just a little more detail on why you did that.

David Bethune: Well, (Harvey) as you know we have multiple technologies. We have Atrigel which we are learning more and more about.

As I ve indicated, we ve been able to put it in to more and more products, and this (areas) deal, transferring this has no effect on the merger we ve made in the internal decision to license this (beamer) technology to (areas) in an effort to put more resources into our topical technology and in to Atrigel.

You know, we have 160 people here. We ve had them all quite busy. And if this transaction is complete, the combined company will receive additional

cash payments from the achievement of developmental and regulatory milestones. And very importantly, (Harvey), I think we should remember that the company will retain co-promotion rights to the (beamer Sentinel) products as it goes along.

So, we retain what we really want, and that is to have the opportunity to have an integrated opportunity with products and that was the one of them.

(Harvey Kubitski): Thank you.

David Bethune: Yes, Sir.

Conference Coordinator: Thank you.

Our next question comes from the site of (Sam Saba) with (Racho) Global.

(ST Telafergada) Yes, hi. It s (ST Telafergada) for (Sam Saba).

Man: Yes.

(ST Telafergada) I was just wondering if you could give us an update on how the integration planning is going with the QLT and when do you expect the shareholder vote to be held?

David Bethune: Well, the integration has not started essentially yet because while we ve had some discussions, and the QLT management has been here to talk to the executives and employees, and I have talked to some of the executives and employees at QLT. We haven t begun the process of the integration although that s just very, very preliminary discussion.

As when do this deal will close is that we do not have definitive date for that closing, and the joint prospective proxy statement is being reviewed by the SEC. And we still hope to close the deal by the end of 2004, but after the SEC review is complete, we will send out definitive proxy, and we will hold a shareholder's meeting so that each and every Atrix shareholder can vote on this transaction.

David Bethune: Great.

Thank you.

Conference Coordinator: Thank you.

Once again, to ask a question, please press star and 1 on your touchtone phone.

And we will take our next question from the site of Jason Aryeh with JALAA Equities.

Jason Aryeh: Congratulations on a great quarter, David.

David Bethune: Thank you, (Jay).

Jason Aryeh: Can you talk a little bit more you were talking about some synergies between QLTI's ocular technology and some of our delivery technology, can you just expound upon that, please?

David Bethune: Well, yeah.

Basically, QLT has expertise in oncology and they're in fact, their I believe their very first product was a photodynamic therapy product for a (soft geo) cancer in which they developed and ultimately was approved for by the FDA and on the US marketplace.

So, they are an oncology knowledge-based company and we are as well. Of course, with Eligard we have an oncology partner for prostate cancer, and we are working on as we indicated to you and shown in our pipeline with Dr. Steve Warren, we have developed the pipeline of oncologic agents. So, there is synergy there.

In the dermatology area, QLT is working on dermatology products. They have PDT product for dermatology, and we have a number of outstanding dermatological products not just the acne type indication as we do with Atrisone, a one that's very close to being submitted to the FDA, but we have products for other areas that I might ask Dr. Warren to comment upon this morning.

And as I indicated earlier, you know, Atrigel has many, many uses, and we've recently determined that Atrigel could be used both systemically and potentially inter-ocularly in ocular disease, which is an increasingly important disease therapy area for all of the major pharmaceutical companies that are now focusing on this particular area. So, there are great synergies.

And of course, we set from the (out set) that we wanted to have we were looking for a possible transaction that would include a company that has great cash flow opportunities to (exploit) the pipeline that we have. We are blessed with the pipeline but weren't so blessed with a massive amount of cash flow to (exploit) that pipeline.

Jason Aryeh:

David...

David Bethune:

Steve, would you like to comment about any of those exciting pipeline products?

Steve Warren:

Sure.

Well, ign="bottom" width="76%">

Contingencies (Note 17)

Minority interests		1.2	1.1
Shareholders' equity (Note 13)			
Common stock (160,761,666 shares issued – 2008; 160,678,695 shares issued – 2007)		767.4	760.3
Retained earnings		1,839.1	1,765.0
Accumulated other comprehensive earnings		236.4	106.9
Treasury stock, at cost (63,080,522 shares – 2008; 60,454,245 shares – 2007)		(1,385.6)	(1,289.7)
Total shareholders' equity		1,457.3	1,342.5
Total Liabilities and Shareholders' Equity	\$	6,446.2	\$ 6,020.6

See accompanying notes to unaudited condensed consolidated financial statements.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Ball Corporation and Subsidiaries

(\$ in millions)

	Three Months Ended	
	March 30, 2008	April 1, 2007
Cash Flows from Operating Activities		
Net earnings	\$ 83.8	\$ 81.2
Adjustments to reconcile net earnings to net cash used in operating activities:		
Depreciation and amortization	74.6	65.0
Gain on sale of subsidiary	(7.1)	—
Deferred taxes	(5.1)	(7.5)
Other, net	(18.1)	14.0
Changes in working capital components, excluding effects of acquisitions and dispositions	(342.7)	(260.4)
Cash used in operating activities	(214.6)	(107.7)
Cash Flows from Investing Activities		
Additions to property, plant and equipment	(74.5)	(88.1)
Proceeds from sale of subsidiary, net of cash sold	8.7	—
Property insurance proceeds (Note 8)	—	48.6
Other, net	(2.3)	2.4
Cash used in investing activities	(68.1)	(37.1)
Cash Flows from Financing Activities		
Long-term borrowings	270.7	215.6
Repayments of long-term borrowings	(32.3)	(103.7)
Change in short-term borrowings	113.7	27.3
Proceeds from issuance of common stock	6.4	11.0
Acquisitions of treasury stock	(131.5)	(98.5)
Common dividends	(9.6)	(10.2)
Other, net	0.4	3.0
Cash provided by financing activities	217.8	44.5
Effect of exchange rate changes on cash	3.2	—
Change in cash and cash equivalents	(61.7)	(100.3)
Cash and cash equivalents - beginning of period	151.6	151.5
Cash and cash equivalents - end of period	\$ 89.9	\$ 51.2

See accompanying notes to unaudited condensed consolidated financial statements.

Notes to Unaudited Condensed Consolidated Financial Statements
Ball Corporation and Subsidiaries

1. Principles of Consolidation and Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the accounts of Ball Corporation and its controlled affiliates (collectively Ball, the company, we or our) and have been prepared by the company without audit. Certain information and footnote disclosures, including critical and significant accounting policies, normally included in financial statements prepared in accordance with generally accepted accounting principles, have been condensed or omitted.

Results of operations for the periods shown are not necessarily indicative of results for the year, particularly in view of the seasonality in the packaging segments. These unaudited condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and the notes thereto included in the company's Annual Report on Form 10-K pursuant to Section 13 of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2007 (annual report).

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. These estimates are based on historical experience and various assumptions believed to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions and conditions. However, we believe that the financial statements reflect all adjustments which are of a normal recurring nature and are necessary for a fair statement of the results for the interim period.

Effective January 1, 2008, Ball adopted Statement of Financial Accounting Standards (SFAS) No. 157, "Fair Value Measurements," and has identified its implications as a critical accounting policy. SFAS No. 157 establishes a framework for measuring fair value and expands disclosures about fair value measurements. Although it does not require any new fair value measurements, the statement emphasizes that fair value is a market-based measurement, not an entity-specific measurement, and should be determined based on the assumptions that market participants would use in pricing the asset or liability. At this time the January 1, 2008, adoption covers only financial assets and liabilities but, subject to a deferral, will be expanded to nonfinancial assets and liabilities as of January 1, 2009, except for those that are recognized or disclosed at fair value in the financial statements on a recurring basis. Details regarding the adoption of SFAS No. 157 and its effects on the company's condensed consolidated financial statements are available in Note 15, "Fair Value of Financial Instruments."

Certain prior-year amounts have been reclassified in order to conform to the current-year presentation.

2. New Accounting Standards

In April 2008 the Financial Accounting Standards Board (FASB) issued FASB Staff Position (FSP) No. 142-3, "Determination of the Useful Life of Intangible Assets." This FSP amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset under FASB Statement No. 142, "Goodwill and Other Intangible Assets." This FSP is effective for Ball as of January 1, 2009, on a prospective basis, and early adoption is prohibited.

In March 2008 the FASB issued SFAS No. 161, "Disclosures About Derivative Instruments and Hedging Activities – an Amendment of FASB Statement No. 133." SFAS No. 161 is intended to enhance the current disclosure requirement in SFAS No. 133. It requires that objectives for using derivative instruments be disclosed in terms of underlying risk and

accounting designation, as well as information about credit-risk-related contingent features. It also requires a company to disclose the fair values of derivative instruments and their gains and losses in a tabular format to make more transparent the location in a company's financial statements of both the derivative positions existing at period end and the effect of using derivatives during the reporting period. The company will also be required to cross-reference within the footnotes to help users of financial statements locate information about derivative instruments. SFAS No. 161 is effective for Ball beginning on January 1, 2009, and is currently under evaluation by the company.

Notes to Consolidated Financial Statements
Ball Corporation and Subsidiaries

2. New Accounting Standards (continued)

In December 2007 the FASB issued SFAS No. 141 (revised 2007), "Business Combinations," which replaces the original SFAS No. 141 issued in June 2001. The new standard retains the fundamental requirements in SFAS No. 141 that the purchase method of accounting be used for all business combinations and for an acquirer to be identified for each business combination. SFAS No. 141 (revised 2007) requires an acquirer to recognize the assets acquired and liabilities assumed measured at their fair values on the acquisition date, which replaces SFAS No. 141's cost-allocation method. SFAS No. 141 (revised 2007) also requires the costs incurred to complete the acquisition and related restructuring costs to be recognized separately from the business combination. The new standard will be effective for Ball on a prospective basis beginning on January 1, 2009.

In April 2007 the FASB issued FSP Interpretation No. (FIN) 39-1, "Amendment of FASB Interpretation No. 39," which amends the terms of FIN 39, paragraph 3 to replace the terms "conditional contracts" and "exchange contracts" with the term "derivative instruments" as defined in SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities." It also amends paragraph 10 of FIN 39 to permit a reporting entity to offset fair value amounts recognized for the right to reclaim cash collateral (a receivable) or the obligation to return cash collateral (a payable) against fair value amounts recognized for derivative instruments executed with the same counterparty under the same master netting arrangement that have been offset in accordance with that paragraph. FSP FIN 39-1 became effective for Ball as of January 1, 2008, and the company has chosen not to offset such positions.

In February 2007 the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities Including an Amendment of FASB Statement No. 115," which permits companies to choose, at specified election dates, to measure certain financial instruments and other eligible items at fair value. Unrealized gains and losses on items for which the fair value option has been elected are subsequently reported in earnings. The decision to elect the fair value option is generally irrevocable, is applied instrument by instrument and can only be applied to an entire instrument. The standard became effective for Ball as of January 1, 2008, and the company did not elect the fair value option for any eligible items.

3. Business Segment Information

Ball's operations are organized and reviewed by management along its product lines in five reportable segments. Due to first quarter 2008 management reporting changes, Ball's People's Republic of China (PRC) operations are now included in the metal beverage packaging, Americas and Asia, segment (previously included with the company's European operations). The results for the quarter ended April 1, 2007, and our financial position at December 31, 2007, have been retrospectively adjusted to conform to the current year presentation.

Metal beverage packaging, Americas and Asia: Consists of operations in the U.S., Canada, Puerto Rico and the PRC, which manufacture and sell metal beverage containers in North America and the PRC, as well as non-beverage plastic containers in the PRC.

Metal beverage packaging, Europe: Consists of operations in several countries in Europe, which manufacture and sell metal beverage containers. Future operations will also include India.

Metal food & household products packaging, Americas: Consists of operations in the U.S., Canada and Argentina, which manufacture and sell metal food cans, aerosol cans, paint cans and custom and specialty cans.

Plastic packaging, Americas: Consists of operations in the U.S. and Canada, which manufacture and sell polyethylene terephthalate (PET) and polypropylene containers, primarily for use in beverage and food packaging. This segment also includes the manufacture and sale of plastic containers used for industrial and household products.

Aerospace and technologies: Consists of the manufacture and sale of aerospace and other related products and the providing of services used primarily in the defense, civil space and commercial space industries.

Notes to Unaudited Condensed Consolidated Financial Statements
Ball Corporation and Subsidiaries

3. Business Segment Information (continued)

The accounting policies of the segments are the same as those in the unaudited condensed consolidated financial statements. A discussion of the company's critical and significant accounting policies can be found in Ball's annual report. We also have investments in companies in the U.S., PRC and Brazil, which are accounted for under the equity method of accounting and, accordingly, those results are not included in segment sales or earnings.

Summary of Business by Segment (\$ in millions)	Three Months Ended	
	March 30, 2008	April 1, 2007
Net Sales		
Metal beverage packaging, Americas & Asia	\$ 703.9	\$ 701.8
Metal beverage packaging, Europe	405.6	320.7
Metal food & household products packaging, Americas	263.8	278.8
Plastic packaging, Americas	188.9	186.6
Aerospace and technologies	178.0	206.3
Net sales	\$ 1,740.2	\$ 1,694.2
Net Earnings		
Metal beverage packaging, Americas & Asia	\$ 74.0	\$ 101.9
Metal beverage packaging, Europe	48.0	36.8
Metal food & household products packaging, Americas	14.8	(0.2)
Plastic packaging, Americas	4.8	2.3
Aerospace and technologies	14.9	19.6
Gain on sale of subsidiary (Note 4)	7.1	—
Total aerospace and technologies	22.0	19.6
Segment earnings before interest and taxes	163.6	160.4
Corporate undistributed expenses, net	(10.2)	(7.7)
Earnings before interest and taxes	153.4	152.7
Interest expense	(36.2)	(37.9)
Tax provision	(37.2)	(36.7)
Minority interests	(0.1)	(0.1)
Equity in results of affiliates	3.9	3.2
Net earnings	\$ 83.8	\$ 81.2

(\$ in millions)	As of	
	March 30, 2008	December 31, 2007
Total Assets		
Metal beverage packaging, Americas & Asia	\$ 1,531.3	\$ 1,400.8
Metal beverage packaging, Europe	2,731.9	2,369.3
Metal food & household products packaging, Americas	1,134.6	1,141.7
Plastic packaging, Americas	566.6	568.8
Aerospace & technologies	272.9	278.7
Segment assets	6,237.3	5,759.3

Edgar Filing: ATRIX LABORATORIES INC - Form 425

Corporate assets, net of eliminations		208.9		261.3
Total assets	\$	6,446.2	\$	6,020.6

Notes to Unaudited Condensed Consolidated Financial Statements
Ball Corporation and Subsidiaries

3. Business Segment Information (continued)

The following table provides the 2007 segment net sales and earnings before interest and taxes had the change in segment presentation for Ball's PRC operations occurred as of January 1, 2007:

(\$ in millions)	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Total 2007
Net sales					
Metal beverage packaging, Americas & Asia	\$ 701.8	\$ 871.2	\$ 711.4(a)	\$ 728.1	\$ 3,012.5
Metal beverage packaging, Europe	320.7	484.8	454.2	393.9	1,653.6
Earnings before interest and taxes					
Metal beverage packaging, Americas & Asia	101.9	89.1	(14.4)(a)	64.2	240.8
Metal beverage packaging, Europe	36.8	86.1	74.8	31.2	228.9

(a) Amounts were reduced by a pretax legal settlement of \$85.6 million.

4. Sale of Subsidiary

On February 15, 2008, Ball Aerospace & Technologies Corp. (BATC) completed the sale of its shares in Ball Solutions Group Pty Ltd (BSG) to QinetiQ Pty Ltd for approximately \$10.5 million, including \$1.8 million of cash sold. BSG was previously a wholly owned Australian subsidiary of BATC that provided services to the Australian department of defense and related government agencies. After an adjustment for working capital items, the sale resulted in a pretax gain of \$7.1 million (\$4.4 million after tax). The sale is not significant to the aerospace and technologies segment's financial statements or its ongoing results.

5. Business Consolidation Activities

2007

Metal Food & Household Products Packaging, Americas

In October 2007 Ball announced plans to close two manufacturing facilities and to exit the custom and decorative tinsplate can business located in Baltimore, Maryland. Ball will close its food and household products packaging facilities in Tallapoosa, Georgia, and Commerce, California, both of which manufacture aerosol and general line cans. The two plant closures will result in a net reduction in manufacturing capacity of 10 production lines, including the relocation of two high-speed aerosol lines into existing Ball facilities. A pretax charge of \$41.9 million (\$25.4 million after tax) was recorded in the fourth quarter in connection with the closure of the aerosol plants, including \$10.7 million for severance costs, \$23 million for the write down to net realizable value of fixed assets, \$2.4 million for excess inventory and \$5.8 million for other associated costs. Cash payments of \$0.2 million were made in the first quarter of 2008 for employee related costs. The remaining reserves are expected to be utilized during 2008. The carrying value of fixed assets remaining for sale in connection with the plant closures was \$8.4 million at March 30, 2008.

Plastic Packaging, Americas

In the fourth quarter of 2007, Ball recorded a pretax charge of \$0.4 million (\$0.2 million after tax) for severance costs related to the termination of approximately 50 employees in response to lost sales. These severance amounts will be paid by the end of 2008.

Notes to Unaudited Condensed Consolidated Financial Statements
Ball Corporation and Subsidiaries

5. Business Consolidation Activities (continued)

2006

Metal Food & Household Products Packaging, Americas

In October 2006 the company announced plans to close two manufacturing facilities in North America as part of the realignment of the metal food and household products packaging, Americas, segment following the acquisition earlier in the year of U.S. Can. A pretax charge of \$33.6 million (\$27.4 million after tax) was recorded in the fourth quarter related to the Burlington, Ontario, plant closure, including \$7.8 million of severance costs, \$16.8 million of pension costs and \$9 million of other costs. The closure of the Alliance, Ohio, plant, estimated to cost approximately \$1 million for employee and other items, was treated as an opening balance sheet item related to the acquisition. Operations have ceased at both plants and payments of \$1.4 million were made in the first quarter of 2008 against the reserves. At March 30, 2008, the remaining reserves included \$1.1 million for employee costs and \$1.2 million for other costs. The carrying value of fixed assets remaining for sale in connection with business consolidation activities was \$12.7 million at March 30, 2008.

2005

Metal Beverage Packaging, Americas and Asia

The company announced in July 2005 the commencement of a project to upgrade and streamline its North American beverage can end manufacturing capabilities. The project is expected to be completed in early 2009 and is resulting in productivity gains and cost reductions. The pretax charge of \$19.3 million (\$11.7 million after tax) recorded in 2005 included \$11.7 million for employee severance, pension and other employee benefit costs; \$1.6 million for decommissioning costs; and \$6 million for the write off of obsolete equipment spare parts and tooling. Payments of \$1.2 million were made in the first quarter of 2008 against the reserve. Severance and other employee benefit costs of \$2.5 million remain at March 30, 2008, all of which are expected to be paid in 2008 and 2009 as the remaining end modules are put into operation. Pension costs will be paid over the retirement period for the affected employees.

6. Receivables

(\$ in millions)	March 30, 2008	December 31, 2007
Trade accounts receivable, net	\$ 606.5	\$ 505.4
Other receivables	68.6	77.3
	\$ 675.1	\$ 582.7

Trade accounts receivable are shown net of an allowance for doubtful accounts of \$16.8 million at March 30, 2008, and \$13.2 million at December 31, 2007. Other receivables include non-income tax receivables, such as property tax and sales tax; certain vendor rebate receivables; and other similar items.

A receivables sales agreement provides for the ongoing, revolving sale of a designated pool of trade accounts receivable of Ball's North American packaging operations, up to \$250 million. The agreement qualifies as off-balance sheet financing under the provisions of SFAS No. 140, as amended by SFAS No. 156. Net funds received from the

sale of the accounts receivable totaled \$238 million at March 30, 2008, and \$170 million at December 31, 2007, and are reflected as a reduction of accounts receivable in the condensed consolidated balance sheets.

Notes to Unaudited Condensed Consolidated Financial Statements
Ball Corporation and Subsidiaries

7. Inventories

(\$ in millions)	March 30, 2008	December 31, 2007
Raw materials and supplies	\$ 396.3	\$ 433.6
Work in process and finished goods	737.7	564.5
	\$ 1,134.0	\$ 998.1

8. Property, Plant and Equipment

(\$ in millions)	March 30, 2008	December 31, 2007
Land	\$ 95.0	\$ 92.2
Buildings	839.4	820.1
Machinery and equipment	3,007.7	2,914.2
Construction in progress	163.0	154.7
	4,105.1	3,981.2
Accumulated depreciation	(2,105.2)	(2,040.0)
	\$ 1,999.9	\$ 1,941.2

Property, plant and equipment are stated at historical cost. Depreciation expense amounted to \$70.2 million and \$61.2 million for the three months ended March 30, 2008, and April 1, 2007, respectively.

On April 1, 2006, a fire in the metal beverage can plant in Hassloch, Germany, damaged a significant portion of the building and machinery and equipment. In accordance with the final agreement reached with the insurance company in November 2006, the final property insurance proceeds of €37.6 million (\$48.6 million) were received in January 2007. Additionally, €8.3 million (\$10.9 million) was recognized during the first quarter of 2007 for insurance recoveries related to business interruption costs.

9. Goodwill

(\$ in millions)	Metal Beverage Packaging, Americas & Asia	Metal Beverage Packaging, Europe	Metal Food & Household Products Packaging, Americas	Plastic Packaging, Americas	Total
Balance at December 31, 2007	\$ 310.1	\$ 1,084.6	\$ 354.3	\$ 114.1	\$ 1,863.1
Effects of foreign currency exchange rates	–	89.5	–	–	89.5
Balance at March 30, 2008	\$ 310.1	\$ 1,174.1	\$ 354.3	\$ 114.1	\$ 1,952.6

In accordance with SFAS No. 142, goodwill is not amortized but instead tested annually for impairment. There has been no goodwill impairment since the adoption of SFAS No. 142 on January 1, 2002.

Notes to Unaudited Condensed Consolidated Financial Statements
Ball Corporation and Subsidiaries

10. Intangibles and Other Assets

(\$ in millions)	March 30, 2008	December 31, 2007
Investments in affiliates	\$ 82.0	\$ 77.6
Intangibles (net of accumulated amortization of \$102 at March 30, 2008, and \$92.9 at December 31, 2007)	119.4	121.9
Company-owned life insurance	94.3	88.9
Noncurrent derivative asset	68.7	-
Deferred tax asset	1.2	4.3
Other	72.9	80.7
	\$ 438.5	\$ 373.4

Total amortization expense of intangible assets amounted to \$4.4 million and \$3.8 million for the first three months of 2008 and 2007, respectively.

11. Debt and Interest Costs

Long-term debt consisted of the following:

(in millions)	March 30, 2008		December 31, 2007	
	In Local Currency	In U.S. \$	In Local Currency	In U.S. \$
Notes Payable				
6.875% Senior Notes, due December 2012 (excluding premium of \$2.5 in 2008 and \$2.7 in 2007)	\$ 550.0	\$ 550.0	\$ 550.0	\$ 550.0
6.625% Senior Notes, due March 2018 (excluding discount of \$0.8 in 2008 and \$0.8 in 2007)	\$ 450.0	450.0	\$ 450.0	450.0
Senior Credit Facilities, due October 2011 (at variable rates)				
Term A Loan, British sterling denominated	82.9	165.3	82.9	164.7
Term B Loan, euro denominated	€ 341.3	539.3	€ 341.3	498.2
Term C Loan, Canadian dollar denominated	C\$ 126.8	124.2	C\$ 126.8	127.6
Term D Loan, U.S. dollar denominated	\$ 487.5	487.5	\$ 487.5	487.5
U.S. dollar multi-currency revolver borrowings	\$ 240.0	240.0	\$ -	-
British sterling multi-currency revolver borrowings	2.1	4.2	2.1	4.2
Industrial Development Revenue Bonds				
Floating rates due through 2015	\$ 9.5	9.5	\$ 13.0	13.0
Other	Various	15.8	Various	13.7
		2,585.8		2,308.9
Less: Current portion of long-term debt		(135.3)		(127.1)
		\$ 2,450.5		\$ 2,181.8

At March 30, 2008, approximately \$465 million was available under the multi-currency revolving credit facilities, which provide for up to \$750 million in U.S. dollar equivalents. The company also had short-term uncommitted credit facilities of up to \$337 million at March 30, 2008, of which \$173.8 million was outstanding and due on demand.

Notes to Unaudited Condensed Consolidated Financial Statements
Ball Corporation and Subsidiaries

11. Debt and Interest Costs (continued)

The notes payable are guaranteed on a full, unconditional and joint and several basis by certain of the company's wholly owned domestic subsidiaries. The notes payable also contain certain covenants and restrictions including, among other things, limits on the incurrence of additional indebtedness and limits on the amount of restricted payments, such as dividends and share repurchases. Exhibit 20 contains unaudited condensed, consolidating financial information for the company, segregating the guarantor subsidiaries and non-guarantor subsidiaries. Separate financial statements for the guarantor subsidiaries and the non-guarantor subsidiaries are not presented because management has determined that such financial statements would not be material to investors.

The company was in compliance with all loan agreements at March 30, 2008, and has met all debt payment obligations. The U.S. note agreements, bank credit agreement and industrial development revenue bond agreements contain certain restrictions relating to dividend payments, share repurchases, investments, financial ratios, guarantees and the incurrence of additional indebtedness.

12. Employee Benefit Obligations

(\$ in millions)	March 30, 2008	December 31, 2007
Total defined benefit pension liability	\$ 440.5	\$ 406.2
Less current portion	(27.9)	(25.7)
Long-term defined benefit pension liability	412.6	380.5
Retiree medical and other postemployment benefits	184.2	193.3
Deferred compensation plans	177.2	185.4
Other	20.6	39.8
	\$ 794.6	\$ 799.0

Components of net periodic benefit cost associated with the company's defined benefit pension plans were:

(\$ in millions)	March 30, 2008			Three Months Ended April 1, 2007		
	U.S.	Foreign	Total	U.S.	Foreign	Total
Service cost	\$ 10.7	\$ 2.3	\$ 13.0	\$ 10.1	\$ 2.2	\$ 12.3
Interest cost	12.7	8.6	21.3	11.7	7.3	19.0
Expected return on plan assets	(16.0)	(4.8)	(20.8)	(13.6)	(4.4)	(18.0)
Amortization of prior service cost	0.3	(0.1)	0.2	0.1	(0.1)	-
Recognized net actuarial loss	2.6	1.0	3.6	3.4	1.2	4.6
Subtotal	10.3	7.0	17.3	11.7	6.2	17.9
Non-company sponsored plans	0.3	-	0.3	0.3	-	0.3
Net periodic benefit cost	\$ 10.6	\$ 7.0	\$ 17.6	\$ 12.0	\$ 6.2	\$ 18.2

Contributions to the company's defined global benefit pension plans, not including the unfunded German plans, were \$6.3 million in the first three months of 2008. The total required contributions to these funded plans are expected to be approximately \$47 million in 2008. Payments to participants in the unfunded German plans were €4.5 million (\$6.7 million) in the first three months of 2008 and are expected to be approximately €18 million (approximately \$28 million) for the full year.

Notes to Unaudited Condensed Consolidated Financial Statements
Ball Corporation and Subsidiaries

13. Shareholders' Equity and Comprehensive Earnings

Accumulated Other Comprehensive Earnings

Accumulated other comprehensive earnings include the cumulative effect of foreign currency translation, pension and other postretirement items and realized and unrealized gains and losses on derivative instruments receiving cash flow hedge accounting treatment.

(\$ in millions)	Foreign Currency Translation	Pension and Other Postretirement Items (net of tax)	Effective Financial Derivatives(a) (net of tax)	Accumulated Other Comprehensive Earnings
December 31, 2007	\$ 221.8	\$ (104.0)	\$ (10.9)	\$ 106.9
Change	86.3	2.0	41.2	129.5
March 30, 2008	\$ 308.1	\$ (102.0)	\$ 30.3	\$ 236.4

(a) Refer to Item 3, "Quantitative and Qualitative Disclosures About Market Risk," for a discussion of the company's use of derivative financial instruments.

Comprehensive Earnings

(\$ in millions)	Three Months Ended	
	March 30, 2008	April 1, 2007
Net earnings	\$ 83.8	\$ 81.2
Foreign currency translation adjustment	86.3	7.8
Pension and other postretirement items	2.0	2.7
Effect of derivative instruments	41.2	4.1
Comprehensive earnings	\$ 213.3	\$ 95.8

Stock-Based Compensation Programs

The company has shareholder-approved stock option plans under which options to purchase shares of Ball common stock have been granted to officers and employees at the market value of the stock at the date of grant. Payment must be made at the time of exercise in cash or with shares of stock owned by the option holder, which are valued at fair market value on the date exercised. In general, options are exercisable in four equal installments commencing one year from the date of grant and terminate 10 years from the date of grant. A summary of stock option activity for the three months ended March 30, 2008, follows:

Outstanding Options	Nonvested Options
---------------------	-------------------

Edgar Filing: ATRIX LABORATORIES INC - Form 425

	Number of Shares	Weighted Average Exercise Price	Number of Shares	Weighted Average Grant Date Fair Value
Beginning of year	4,747,005	\$ 32.06	1,664,980	\$ 10.88
Vested			-	-
Exercised	(47,593)	18.84		
Canceled/forfeited	(16,400)	43.28	(16,200)	10.70
End of period	4,683,012	32.16	1,648,780	10.88
Vested and exercisable, end of period	3,034,232	24.52		
Reserved for future grants	4,777,777			

Notes to Unaudited Condensed Consolidated Financial Statements
Ball Corporation and Subsidiaries

13. Shareholders' Equity and Comprehensive Earnings (continued)

The weighted average remaining contractual term for all options outstanding at March 30, 2008, was 6 years and the aggregate intrinsic value (difference in exercise price and closing price at that date) was \$60.8 million. The weighted average remaining contractual term for options vested and exercisable at March 30, 2008, was 4.6 years and the aggregate intrinsic value was \$62.6 million. The company received \$0.9 million from options exercised during the three months ended March 30, 2008. The intrinsic value associated with these exercises was \$1.2 million, and the associated tax benefit of \$0.4 million was reported as other financing activities in the condensed consolidated statement of cash flows.

In addition to stock options, the company may issue to officers and certain employees restricted shares and restricted stock units, which vest over various periods but, other than the performance-contingent grants discussed below, generally in equal installments over five years. Compensation cost is recorded based upon the fair value of the shares at the grant date.

To encourage certain senior management employees and outside directors to invest in Ball stock, Ball adopted a deposit share program in March 2001 (subsequently amended and restated in April 2004) that matches purchased shares with restricted shares. In general, restrictions on the matching shares lapse at the end of four years from date of grant, or earlier in stages if established share ownership guidelines are met, assuming the relevant qualifying purchased shares are not sold or transferred prior to that time. Grants under the plan are accounted for as equity awards and compensation expense is recorded based upon the fair value of the shares at the grant date.

In April 2007 the company's board of directors granted 170,000 performance-contingent restricted stock units to key employees, which will cliff vest if the company's return on average invested capital during a 33-month performance period is equal to or exceeds the company's cost of capital. If the performance goal is not met, the shares will be forfeited. Current assumptions are that the performance targets will be met and, accordingly, grants under the plan are being accounted for as equity awards and compensation expense is recorded based upon the fair value (closing market price) of the shares at the grant date. On a quarterly basis, the company reassesses the probability of the goal being met and adjusts compensation expense as appropriate. No such adjustment was considered necessary at the end of the first quarter 2008.

For the three months ended March 30, 2008, the company recognized pretax expense of \$4.2 million (\$2.6 million after tax) for share-based compensation arrangements, which represented \$0.03 per basic and diluted share. For the three months ended April 1, 2007, the company recognized pretax expense of \$3.1 million (\$1.9 million after tax) for such arrangements, which represented \$0.02 per basic and diluted share. At March 30, 2008, there was \$28.5 million of total unrecognized compensation costs related to nonvested share-based compensation arrangements. This cost is expected to be recognized in earnings over a weighted average period of 2.4 years.

Stock Repurchase Agreements

Through the first quarter of 2008, we repurchased \$125 million of our common stock, net of issuances, including a \$31 million settlement on January 7, 2008, of a forward contract entered into in December 2007 for the repurchase of 675,000 shares.

Ball's first quarter 2008 net share repurchases also included the preliminary settlement of an accelerated share repurchase agreement entered into in December 2007 to buy \$100 million of the company's common shares. Ball

advanced the \$100 million on January 7, 2008, and received approximately 2 million shares, which represented 90 percent of the total shares as calculated using the previous day's closing price. The exact number of shares to be repurchased under the agreement, which will be determined on the settlement date (no later than June 5, 2008), is subject to an adjustment based on a weighted average price calculation for the period between the initial purchase date and the settlement date. The company has the option to settle the contract in either cash or shares.

Notes to Unaudited Condensed Consolidated Financial Statements
Ball Corporation and Subsidiaries

14. Earnings Per Share

(\$ in millions, except per share amounts; shares in thousands)	Three Months Ended	
	March 30, 2008	April 1, 2007
Diluted Earnings per Share:		
Net earnings	\$ 83.8	\$ 81.2
Weighted average common shares	97,199	102,110
Effect of dilutive securities	1,390	1,705
Weighted average shares applicable to diluted earnings per share	98,589	103,815
Diluted earnings per share	\$ 0.85	\$ 0.78

Information needed to compute basic earnings per share is provided in the condensed consolidated statements of earnings.

15. Fair Value of Financial Instruments

Ball adopted SFAS No. 157 effective January 1, 2008, for financial assets and liabilities measured on a recurring basis. As discussed in Note 1, SFAS No. 157 establishes a framework for measuring value and expands disclosures about fair value measurements. Although it does not require any new fair value measurements, the statement emphasizes that fair value is a market-based measurement, not an entity-specific measurement, and should be determined based on the assumptions that market participants would use in pricing the asset or liability. As defined in SFAS No. 157, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). However, it permits a mid-market pricing convention (the mid-point price between bid and ask prices) as a practical expedient. SFAS No. 157 requires that the fair value of a liability include the nonperformance risk (including entity's credit risk and other risks such as settlement risk) related to the liability being measured.

The statement establishes a fair value hierarchy that prioritizes the inputs used to measure fair value using the following definitions (from highest to lowest priority):

Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 1 primarily consists of financial instruments, such as exchange-traded derivatives and listed equity securities.

Level 2 – Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category include non-exchange-traded derivatives, such as over-the-counter forwards and options.

Level 3 – Prices or valuation techniques requiring inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Notes to Unaudited Condensed Consolidated Financial Statements
Ball Corporation and Subsidiaries

15. Fair Value of Financial Instruments (continued)

The following table summarizes by level within the fair value hierarchy the company's financial assets and liabilities accounted for at fair value on a recurring basis as of March 30, 2008. The company's assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.

(\$ in millions)	Level 1	Level 2	Total
Assets:			
Current commodity derivatives (a)	\$ –	\$ 68.7	\$ 68.7
Noncurrent commodity derivatives (b)	–	58.5	58.5
Nonmonetary exchanges (c)	–	23.9	23.9
Other assets	–	6.0	6.0
Total assets	\$ –	\$ 157.1	\$ 157.1
Liabilities:			
Current commodity derivatives (d)	\$ –	\$ 49.5	\$ 49.5
Noncurrent commodity derivatives (e)	–	37.6	37.6
Deferred compensation liabilities (f)	109.2	68.0	177.2
Other liabilities	–	6.5	6.5
Total liabilities	\$ 109.2	\$ 161.6	\$ 270.8

(a) Amounts are included in the consolidated balance sheet within deferred taxes and other current assets.

(b) Amounts are included in the consolidated balance sheet within intangibles and others assets, net.

(c) Amounts are included in the consolidated balance sheet within receivables, net.

(d) Amounts are included in the consolidated balance sheet within other current liabilities.

(e) Amounts are included in the consolidated balance sheet within deferred taxes and other liabilities.

(f) See Note 12.

The company has not identified any Level 3 items at March 30, 2008. The fair value of the company's pension assets will be evaluated under SFAS No. 157 as of December 31, 2008, as part of the year-end valuation of the company's pension benefit obligations.

The company uses closing spot and forward market prices as published by the London Metal Exchange, Reuters and Bloomberg to determine the fair value of its aluminum, currency and interest rate spot and forward contracts. Option contracts are valued using a Black Scholes model with observable market inputs for aluminum, currency and interest rates. The company additionally evaluates counterparty creditworthiness to determine if any adjustment to fair value is needed, and since the company's financial derivatives are traded in highly liquid markets, no illiquidity reserve is taken against the determined fair value.

For the three months ended March 30, 2008, the company recorded a net pretax loss of \$2.6 million for the changes in the fair value of its derivative instruments, the majority of which is expected to reverse in future periods.

As permitted, the company's long-term debt is not carried in the company's financial statements at fair value. The fair value of the long-term debt was estimated at \$2,596.2 million as of March 30, 2008, as compared to its carrying value of \$2,585.8 million. Rates currently available to the company for loans with similar terms and maturities are used to

estimate the fair value of long-term debt based on cash flows.

Notes to Unaudited Condensed Consolidated Financial Statements
Ball Corporation and Subsidiaries

16. Subsequent Event

On April 23, 2008, the company announced plans to close a U.S. metal beverage packaging plant in Kent, Washington. The plant operates two, 12-ounce aluminum beverage can manufacturing lines that produce approximately 1.1 billion cans annually. Those lines will be redeployed to generate higher returns on those assets elsewhere in Ball's worldwide system. A pretax charge of approximately \$12 million (\$7 million after tax) will be recorded in the second quarter results, and the plant is expected to be shut down during the third quarter of 2008.

17. Contingencies

The company is subject to various risks and uncertainties in the ordinary course of business due, in part, to the competitive nature of the industries in which the company participates. We do business in countries outside the U.S., have changing commodity prices for the materials used in the manufacture of our packaging products and participate in changing capital markets. Where management considers it warranted, we reduce these risks and uncertainties through the establishment of risk management policies and procedures, including, at times, the use of certain derivative financial instruments.

From time to time, the company is subject to routine litigation incident to its businesses. Additionally, the U.S. Environmental Protection Agency has designated Ball as a potentially responsible party, along with numerous other companies, for the cleanup of several hazardous waste sites. Our information at this time does not indicate that these matters will have a material adverse effect upon the liquidity, results of operations or financial condition of the company.

18. Indemnifications and Guarantees

During the normal course of business, the company or its appropriate consolidated direct or indirect subsidiaries have made certain indemnities, commitments and guarantees under which the specified entity may be required to make payments in relation to certain transactions. These indemnities, commitments and guarantees include indemnities to the customers of the subsidiaries in connection with the sales of their packaging and aerospace products and services; guarantees to suppliers of direct or indirect subsidiaries of the company guaranteeing the performance of the respective entity under a purchase agreement, construction contract or other commitment; guarantees in respect of certain foreign subsidiaries' pension plans; indemnities for liabilities associated with the infringement of third party patents, trademarks or copyrights under various types of agreements; indemnities to various lessors in connection with facility, equipment, furniture and other personal property leases for certain claims arising from such leases; indemnities to governmental agencies in connection with the issuance of a permit or license to the company or a subsidiary; indemnities pursuant to agreements relating to certain joint ventures; indemnities in connection with the sale of businesses or substantially all of the assets and specified liabilities of businesses; and indemnities to directors, officers and employees of the company to the extent permitted under the laws of the State of Indiana and the United States of America. The duration of these indemnities, commitments and guarantees varies, and in certain cases, is indefinite. In addition, the majority of these indemnities, commitments and guarantees do not provide for any limitation on the maximum potential future payments the company could be obligated to make. As such, the company is unable to reasonably estimate its potential exposure under these items.

The company has not recorded any liability for these indemnities, commitments and guarantees in the accompanying condensed consolidated balance sheets. The company does, however, accrue for payments under promissory notes and other evidences of incurred indebtedness and for losses for any known contingent liability, including those that may arise from indemnifications, commitments and guarantees, when future payment is both reasonably determinable and

probable. Finally, the company carries specific and general liability insurance policies and has obtained indemnities, commitments and guarantees from third party purchasers, sellers and other contracting parties, which the company believes would, in certain circumstances, provide recourse to any claims arising from these indemnifications, commitments and guarantees.

Notes to Unaudited Condensed Consolidated Financial Statements
Ball Corporation and Subsidiaries

18. Indemnifications and Guarantees (continued)

The company's senior notes and senior credit facilities are guaranteed on a full, unconditional and joint and several basis by certain of the company's wholly owned domestic subsidiaries. Foreign tranches of the senior credit facilities are similarly guaranteed by certain of the company's wholly owned foreign subsidiaries. These guarantees are required in support of the notes and credit facilities referred to above, are co-terminous with the terms of the respective note indentures and credit agreement and would require performance upon certain events of default referred to in the respective guarantees. The maximum potential amounts which could be required to be paid under the guarantees are essentially equal to the then outstanding principal and interest under the respective notes and credit agreement, or under the applicable tranche. The company is not in default under the above notes or credit facilities.

Ball Capital Corp. II is a separate, wholly owned corporate entity created for the purchase of receivables from certain of the company's wholly owned subsidiaries. Ball Capital Corp. II's assets will be available first to satisfy the claims of its creditors. The company has provided an undertaking to Ball Capital Corp. II in support of the sale of receivables to a commercial lender or lenders who would require performance upon certain events of default referred to in the undertaking. The maximum potential amount which could be paid is equal to the outstanding amounts due under the accounts receivable financing (see Note 6). The company, the relevant subsidiaries and Ball Capital Corp. II are not in default under the above credit arrangement.

From time to time, the company is subject to claims arising in the ordinary course of business. In the opinion of management, no such matter, individually or in the aggregate, exists which is expected to have a material adverse effect on the company's consolidated results of operations, financial position or cash flows.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management's discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and the accompanying notes. Ball Corporation and its subsidiaries are referred to collectively as "Ball" or the "company" or "we" or "our" in the following discussion and analysis.

BUSINESS OVERVIEW

Ball Corporation is one of the world's leading suppliers of metal and plastic packaging to the beverage, food and household products industries. Our packaging products are produced for a variety of end uses and are manufactured in plants around the world. Our wholly owned subsidiary, Ball Aerospace & Technologies Corp. (BATC), also supplies aerospace and other technologies and services to governmental and commercial customers.

We sell our packaging products primarily to major beverage, food and household products companies with which we have developed long-term customer relationships. This is evidenced by our high customer retention and our large number of long-term supply contracts. While we have diversified our customer base, we do sell a majority of our packaging products to relatively few major companies in North America, Europe, the People's Republic of China (PRC) and Argentina, as do our equity joint ventures in Brazil, the U.S. and the PRC. We also purchase raw materials from relatively few suppliers. Because of our customer and supplier concentration, our business, financial condition and results of operations could be adversely affected by the loss of a major customer or supplier or a change in a supply agreement with a major customer or supplier, although our contracts and long-term relationships mitigate these risks.

In the rigid packaging industry, sales and earnings can be improved by reducing costs, developing new products, expanding volume and increasing prices. In 2009 we expect to complete the project to upgrade and streamline our North American beverage can end manufacturing capabilities, a project that in 2007 began to generate productivity gains and cost reductions in the metal beverage packaging, Americas and Asia, segment.

While the U.S. and Canadian beverage container manufacturing industry is relatively mature, the European, PRC and Brazilian beverage can markets are growing and are expected to continue to grow. We are capitalizing on this growth by increasing capacity in some of our European can manufacturing facilities by speeding up certain lines and by expansion. We recently announced expansion plans with our intention to build a beverage can manufacturing plant in India, as well as a new plant in Poland, to meet the rapidly growing demand for beverage cans there and in central and eastern Europe. To better position the company in the European market, the capacity from the fire-damaged Hassloch, Germany, plant was replaced with a mix of steel beverage can manufacturing capacity in the Hassloch plant and aluminum beverage can manufacturing capacity in the company's Hermsdorf, Germany, plant. All three lines were in commercial production by the end of the second quarter of 2007. We are also considering additional can and end manufacturing capacity in Europe and in the PRC. Additionally, we recently announced a new one-line metal beverage can plant in our Brazil joint venture and are adding further 16-ounce can capacity in another Brazil can plant. These Brazil expansion efforts will be owned by Ball's unconsolidated 50-percent owned joint venture, Latapack-Ball Embalagens, Ltda., with the financing anticipated to be funded by cash flows from the joint venture.

As part of our packaging strategy, we are focused on developing and marketing new and existing products that meet the needs of our customers and the consumer. These innovations include new shapes, sizes, opening features and other functional benefits of both metal and plastic packaging. This packaging development activity helps us maintain and expand our supply positions with major beverage, food and household products customers. As part of this focus, we are installing a new 24-ounce beverage can production line in our Monticello, Indiana, facility. The line is expected to be operational in mid-2008. We are also developing a portfolio of new products including Alumi-Tek™, vented end,

recloseable end and gamma clear items, among others.

Ball's consolidated earnings are exposed to foreign exchange rate fluctuations. We attempt to mitigate this exposure through the use of derivative financial instruments, as discussed in "Quantitative and Qualitative Disclosures About Market Risk" within Item 3 of this report.

The primary customers for the products and services provided by our aerospace and technologies segment are U.S. government agencies or their prime contractors. It is possible that federal budget reductions and priorities, or changes in agency budgets, could limit future funding and new contract awards or delay or prolong contract performance.

We recognize sales under long-term contracts in the aerospace and technologies segment using the cost-to-cost, percentage of completion method of accounting. Our present contract mix consists of approximately 70 percent cost-type contracts, which are billed at our costs plus an agreed upon and/or earned profit component, while the remainder are fixed price contracts. We include time and material contracts in the fixed price category because such contracts typically provide for the sale of engineering labor at fixed hourly rates. Failure to be awarded certain key contracts could adversely affect segment performance.

Throughout the period of contract performance, we regularly reevaluate and, if necessary, revise our estimates of BATC's total contract revenue, total contract cost and progress toward completion. Because of contract payment schedules, limitations on funding and other contract terms, our sales and accounts receivable for this segment include amounts that have been earned but not yet billed.

Management uses various measures to evaluate company performance. The primary financial metric we use is economic value added (tax-effected operating earnings, as defined by the company, less a charge for net operating assets employed). Our goal is to increase economic value added on an annual basis. Other financial metrics we use are earnings before interest and taxes (EBIT); earnings before interest, taxes, depreciation and amortization (EBITDA); diluted earnings per share; operating cash flow and free cash flow (generally defined by the company as cash flow from operating activities less capital expenditures). These financial measures may be adjusted at times for items that affect comparability between periods. Nonfinancial measures in the packaging segments include production efficiency and spoilage rates, quality control figures, environmental, health and safety statistics and production and shipment volumes. Additional measures used to evaluate performance in the aerospace and technologies segment include contract revenue realization, award and incentive fees realized, proposal win rates and backlog (including awarded, contracted and funded backlog).

We recognize that attracting, developing and retaining highly talented employees are essential to the success of Ball and, because of this, we strive to pay employees competitively and encourage their ownership of the company's common stock as part of a diversified portfolio. For most management employees, a meaningful portion of compensation is at risk as an incentive, dependent upon economic value-added operating performance. For more senior positions, more compensation is at risk through economic value-added performance and various stock compensation plans. Through our employee stock purchase plan and 401(k) plan, which matches employee contributions with Ball common stock, employees, regardless of organizational level, have opportunities to own Ball stock.

CONSOLIDATED SALES AND EARNINGS

The company has five reportable segments organized along a combination of product lines and geographic areas: (1) metal beverage packaging, Americas and Asia; (2) metal beverage packaging, Europe; (3) metal food and household products packaging, Americas; (4) plastic packaging, Americas; and (5) aerospace and technologies. Due to first quarter 2008 management reporting changes, Ball's PRC operations are now included in the metal beverage packaging, Americas and Asia, segment. The 2007 segment information has been retrospectively adjusted to conform to the current year presentation. We also have investments in companies in the U.S., the PRC and Brazil, which are accounted for using the equity method of accounting and, accordingly, those results are not included in segment sales or earnings.

Metal Beverage Packaging, Americas and Asia

The metal beverage packaging, Americas and Asia, segment consists of operations located in the U.S., Canada, Puerto Rico and the PRC, which manufacture metal container products used in beverage packaging, as well as non-beverage plastic containers manufactured and sold mainly in the PRC. This segment accounted for 41 percent of consolidated net sales in the first three months of 2008 (41 percent in 2007). Sales in 2008 were essentially flat compared to 2007 as higher sales prices in 2008, primarily due to rising aluminum prices, were offset by an overall decrease in volumes of more than 4 percent. The decrease in North American sales volumes was somewhat offset by a 6 percent sales volume increase in the PRC. Lower first quarter sales volumes in North America were caused in part by the loss of certain 12-ounce beer can business that the company decided not to continue.

First quarter segment earnings of \$74 million were lower than first quarter 2007 earnings of \$101.9 million primarily due to approximately \$43 million of raw material inventory gains realized in 2007 not recurring in 2008. First quarter 2008 earnings were favorably impacted by higher sales prices and improved sales mix totaling approximately \$9 million and positive cost impacts from the new end technology projects and other cost saving measures totaling approximately \$6 million.

We continue to focus efforts on the growing custom beverage can business, which includes cans of different shapes, diameters and fill volumes, and cans with added functional attributes (such as recloseability) for new products and product line extensions.

Subsequent Event

On April 23, 2008, the company announced plans to close a U.S. metal beverage packaging plant in Kent, Washington. The plant operates two, 12-ounce aluminum beverage can manufacturing lines that produce approximately 1.1 billion cans annually. Those lines will be redeployed to generate higher returns on those assets elsewhere in Ball's worldwide system. A pretax charge of approximately \$12 million (\$7 million after tax) will be recorded in the second quarter results, and the plant is expected to cease production during the third quarter of 2008. On final disposition of the plant and equipment, the closure is expected to be approximately \$4 million cash positive inclusive of income tax benefits.

Metal Beverage Packaging, Europe

The metal beverage packaging, Europe, segment includes metal beverage packaging products manufactured and sold mainly in Europe. This segment accounted for 23 percent of consolidated net sales in the first three months of 2008 (19 percent in 2007). Segment sales in the first quarter of 2008 were 26 percent higher compared to the same period of the prior year due largely to 13 percent higher volumes consistent with overall market growth and 13 percent related to foreign currency gains on the strength of the euro. Higher segment sales volumes were aided by the growth in Europe of custom can volumes, including the successful introduction of the Ball sleek can into Italy. The slow return of the metal beverage can to the German market, following the mandatory deposit legislation previously reported on, is being augmented by stronger demand outside Germany.

Segment earnings were \$48 million in the first three months of 2008 compared to \$36.8 million for the same period in 2007. Earnings in 2008 were approximately \$39 million higher due to the combination of increased sales volumes and price recovery initiatives, as well as \$4 million related to a stronger euro. These improvements were partially offset by \$34 million of higher raw material, freight and energy costs.

On April 1, 2006, a fire in the metal beverage can plant in Hassloch, Germany, damaged a significant portion of the building and machinery and equipment. In accordance with the final agreement reached with the insurance company in November 2006, the final property insurance proceeds of €37.6 million (\$48.6 million) were received in January 2007. Additionally, €8.3 million (\$10.9 million) was recognized in the first quarter of 2007 for insurance recoveries related to business interruption costs and is contemplated in the earnings improvement discussed above.

Metal Food & Household Products Packaging, Americas

The metal food and household products packaging, Americas, segment consists of operations located in the U.S., Canada and Argentina. The segment includes the manufacture and sale of metal cans used for food packaging, aerosol cans, paint cans and decorative specialty cans.

Segment sales in the first quarter of 2008 constituted 15 percent of consolidated net sales (17 percent in 2007). First quarter 2008 sales were 5 percent lower than in the first quarter of 2007 due to lower preseason shipments to seasonal customers and decisions by management to discontinue unprofitable business, resulting in the closure of our Commerce, California, and Tallapoosa, Georgia, facilities.

First quarter segment earnings were \$14.8 million compared to a loss of \$0.2 million in the same period last year. The performance in the first quarter of 2008 was primarily related to lower manufacturing costs and efficiencies in the first quarter of 2008 attributable to ongoing integration efforts related to the closure of Ball's Burlington, Ontario, manufacturing facility in the fourth quarter of 2006. First quarter 2008 earnings also reflect improved pricing and manufacturing performance, partially offset by lower sales volumes as customers worked off higher 2007 year end finished goods inventories.

The company announced in the fourth quarter of 2007 that by the end of 2008 it would close metal food and household products packaging plants in Commerce, California, and Tallapoosa, Georgia. Additional details regarding business consolidation activities are available in Note 5 accompanying the unaudited condensed consolidated financial statements included within Item 1 of this report.

Plastic Packaging, Americas

The plastic packaging, Americas, segment consists of operations located in the U.S. and Canada, which manufacture polyethylene terephthalate (PET) and polypropylene plastic container products used mainly in beverage and food packaging, as well as high density polyethylene and polypropylene containers for industrial and household product applications.

Segment sales, which accounted for 11 percent of consolidated net sales in the first quarter of 2008 (11 percent in 2007), were up \$2.3 million compared to the same period in 2007. The increase was primarily the result of raw material cost increases passed through, which accounted for approximately \$20 million of the increase. This increase in net sales was offset by 5 percent lower bottle sales volumes due to a decrease in carbonated soft drink and water bottle sales, partially offset by higher sales in specialty business markets (e.g., custom hot-fill, alcohol, food and juice drinks) and decreased preform sales due to Ball's decision to forego certain low margin business.

Segment earnings of \$4.8 million in the first three months of 2008 were higher than prior year earnings of \$2.3 million largely due to the previously mentioned increase in specialty business sales partially offset by the lower carbonated soft drink, water and preform sales volumes.

In view of the substandard PET margins, we continue to focus our efforts on margin recovery initiatives, as well as PET development efforts in the custom hot-fill, beer, wine, flavored alcoholic beverage and specialty container markets. In the polypropylene plastic container arena, development efforts are primarily focused on custom packaging markets.

Aerospace and Technologies

Aerospace and technologies segment sales, which represented 10 percent of consolidated net sales in the first quarter of 2008 (12 percent in 2007), were 14 percent lower than in the first quarter of 2007. The reduction is the result of a combination of large programs winding down and program terminations and delays due to government funding constraints. The reductions were partially offset by new program starts and increased scope on previously awarded contracts.

On February 15, 2008, BATC completed the sale of its shares in Ball Solutions Group Pty Ltd (BSG) to QinetiQ Pty Ltd for approximately \$10.5 million, including cash sold of \$1.8 million. BSG was previously a wholly owned Australian subsidiary of BATC that provided services to the Australian department of defense and related government agencies. After an adjustment for working capital items, the sale resulted in a pretax gain of \$7.1 million (\$4.4 million after tax). Segment earnings of \$22 million in the first three months of 2008 included this gain. On a comparable basis, segment earnings were \$14.9 million compared to \$19.6 million for the same period in 2007. Excluding the gain

on sale, earnings were lower in 2008 than in 2007 as a result of the lower sales and a number of nonrecurring favorable program profit adjustments in 2007.

Contracted backlog in the aerospace and technologies segment at March 30, 2008, was \$727 million compared to a backlog of \$774 million at December 31, 2007. Comparisons of backlog are not necessarily indicative of the trend of future operations.

Additional Segment Information

For additional information on our segment operations, see the Business Segment Information in Note 3 accompanying the unaudited condensed consolidated financial statements included within Item 1 of this report.

Selling, General and Administrative

Selling, general and administrative (SG&A) expenses were \$81.6 million in the first quarter of 2008 compared to \$82.2 million for the same period in 2007. Lower research and development costs of \$4 million and other miscellaneous net cost reductions in 2008 were partially offset by \$1 million of higher stock-based compensation and a \$2 million increase in bad debt expense.

Interest and Taxes

Consolidated interest expense was \$36.2 million for the first three months of 2008 compared to \$37.9 million in the same period of 2007. The reduced expense in 2008 was primarily due to lower interest rates.

While the effective income tax rate was approximately 32 percent for the first quarters of both 2008 and 2007, the rate in 2008 was favorably impacted by the earnings mix increasing in lower taxed jurisdictions, including Germany and the United Kingdom, which had enacted rate reductions effective January 1, 2008. This was somewhat offset by a decrease in U.S. foreign tax credit utilization and the U.S. research and development credit expiring at the end of 2007.

NEW ACCOUNTING PRONOUNCEMENTS

For information regarding recent accounting pronouncements, see Note 2 to the unaudited condensed consolidated financial statements within Item 1 of this report.

FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

Our primary sources of liquidity are cash provided by operating activities and external borrowings. We believe that cash flows from operations and cash provided by short-term and revolver borrowings, when necessary, will be sufficient to meet our ongoing operating requirements, scheduled principal and interest payments on debt, dividend payments and anticipated capital expenditures. However, our liquidity could be impacted significantly by a decrease in demand for our products, which could arise from competitive circumstances, or any of the other factors described in Item 1A, "Risk Factors," within the company's annual report.

Cash flows used in operations were \$214.6 million in the first three months of 2008 compared to \$107.7 million in the first three months of 2007. The reduction in 2008 was primarily due to the approximately \$70 million payment in January of a legal settlement to a customer, as well as a higher increase in seasonal inventories, partially offset by an increase in the accounts receivable sales program.

Based on information currently available, we estimate 2008 capital spending to be approximately \$350 million compared to 2007 capital spending of \$259.9 million (net of \$48.6 million in insurance recoveries). Approximately 75 percent of the total capital spending will be in the metal beverage can segments and more than 50 percent of the total spending will be for new top-line growth projects. The 2008 capital spending projection includes the effects of foreign currency exchange rates as many of our capital projects will occur in Europe.

Interest-bearing debt increased to \$2,759.6 million at March 30, 2008, compared to \$2,358.6 million at December 31, 2007, primarily due to seasonal working capital needs, higher common stock repurchases and a higher euro exchange rate. We intend to allocate our operating cash flow in 2008 to capital spending programs, common stock repurchases and dividends. Our stock repurchase program, net of issuances, is expected to be in the range of \$300 million in 2008 compared to \$211.3 million in 2007. Through the first quarter of 2008, we repurchased \$125 million of our common stock, net of issuances, including a \$31 million settlement on January 7, 2008, of a forward contract entered into in December 2007 for the repurchase of 675,000 shares.

Ball's first quarter 2008 net share repurchases also included the preliminary settlement of an accelerated share repurchase agreement entered into in December 2007 to buy \$100 million of the company's common shares. Ball advanced the \$100 million on January 7, 2008, and received approximately 2 million shares, which represented 90 percent of the total shares as calculated using the previous day's closing price. The exact number of shares to be repurchased under the agreement, which will be determined on the settlement date (no later than June 5, 2008), is subject to an adjustment based on a weighted average price calculation for the period between the initial purchase date and the settlement date. The company has the option to settle the contract in either cash or shares.

Total required contributions to the company's defined benefit plans, not including the unfunded German plans, are expected to be approximately \$47 million in 2008. This estimate may change based on plan asset performance, the revaluation of the plans' liabilities later in 2008 and revised estimates of 2008 full-year cash flows. Payments to participants in the unfunded German plans are expected to be approximately €18 million (approximately \$28 million) for the full year.

At March 30, 2008, approximately \$465 million was available under the company's multi-currency revolving credit facilities. In addition, the company had short-term uncommitted credit facilities of \$337 million at the end of the first quarter, of which \$173.8 million was outstanding.

The company has a receivables sales agreement that provides for the ongoing, revolving sale of a designated pool of trade accounts receivable of Ball's North American packaging operations, up to \$250 million. The agreement qualifies as off-balance sheet financing under the provisions of Statement of Financial Accounting Standards (SFAS) No. 140, as amended by SFAS No. 156. Net funds received from the sale of the accounts receivable totaled \$238 million at March 30, 2008, and \$170 million at December 31, 2007, and are reflected as a reduction of accounts receivable in the condensed consolidated balance sheets.

The company was in compliance with all loan agreements at March 30, 2008, and has met all debt payment obligations. Additional details about the company's debt and receivables sales agreement are available in Notes 11 and 6, respectively, accompanying the unaudited condensed consolidated financial statements included within Item 1 of this report.

CONTINGENCIES, INDEMNIFICATIONS AND GUARANTEES

Details about the company's contingencies, indemnifications and guarantees are available in Notes 17 and 18 accompanying the unaudited condensed consolidated financial statements included within Item 1 of this report.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

In the ordinary course of business, we employ established risk management policies and procedures to reduce our exposure to fluctuations in commodity prices, interest rates, foreign currencies and prices of the company's common stock in regard to common share repurchases. Although the instruments utilized involve varying degrees of credit, market and interest risk, the counterparties to the agreements are expected to perform fully under the terms of the agreements.

We have estimated our market risk exposure using sensitivity analysis. Market risk exposure has been defined as the changes in fair value of derivative instruments, financial instruments and commodity positions. To test the sensitivity of our market risk exposure, we have estimated the changes in fair value of market risk sensitive instruments assuming a hypothetical 10 percent adverse change in market prices or rates. The results of the sensitivity analysis are summarized below.

Commodity Price Risk

We manage our North American commodity price risk in connection with market price fluctuations of aluminum primarily by entering into container sales contracts that include aluminum-based pricing terms that generally reflect price fluctuations under our commercial supply contracts for aluminum purchases. The terms include fixed, floating or pass-through aluminum component pricing. This matched pricing affects substantially all of our North American metal beverage packaging net sales. We also, at times, use certain derivative instruments such as option and forward contracts as cash flow and fair value hedges of commodity price risk where there is not a pass-through arrangement in the sales contract.

Most of the plastic packaging, Americas, sales contracts include provisions to fully pass through resin cost changes. As a result, we believe we have minimal exposure related to changes in the cost of plastic resin. Most metal food and household products packaging, Americas, sales contracts either include provisions permitting us to pass through some or all steel cost changes we incur, or they incorporate annually negotiated steel costs. In 2008 and in 2007, we were able to pass through to our customers the majority of steel cost increases. We anticipate that we will be able to pass through the majority of the steel price increases that occur over the next twelve months.

In Europe and the PRC, the company manages the aluminum and steel raw material commodity price risks through annual and long-term contracts for the purchase of the materials, as well as certain sales of containers, that reduce the company's exposure to fluctuations in commodity prices within the current year. These purchase and sales contracts include fixed price, floating and pass-through pricing arrangements. We also use forward and option contracts as cash flow hedges to manage future aluminum price risk and foreign exchange exposures for those sales contracts where there is not a pass-through arrangement to minimize the company's exposure to significant price changes.

The company had aluminum contracts hedging its aluminum exposure with notional amounts of approximately \$1 billion at March 30, 2008, and December 31, 2007. The aluminum contracts include cash flow and fair value hedges that offset sales contracts of various terms and lengths, as well as other derivative instruments for which the company elects mark-to-market accounting. Cash flow and fair value hedges related to forecasted transactions and firm commitments expire within the next four years. Included in shareholders' equity at March 30, 2008, within accumulated other comprehensive earnings, is a net after-tax gain of \$28 million associated with these contracts, of which a net gain of \$14 million is expected to be recognized in the consolidated statement of earnings during the next twelve months. The net gain on these derivative contracts will be passed through to customers by lower revenue from sales contracts. Additional details about the company's unsettled commodity derivative contracts are available in Note 15 accompanying the unaudited condensed consolidated financial statements included within Item 1 of this report.

Considering the effects of derivative instruments, the company's ability to pass through certain raw material costs through contractual provisions, the market's ability to accept price increases and the company's commodity price exposures under its contract terms, a hypothetical 10 percent adverse change in the company's steel, aluminum and resin prices could result in an estimated \$8 million after-tax reduction in net earnings over a one-year period. Additionally, if foreign currency exchange rates were to change adversely by 10 percent, we estimate there could be a \$14 million after-tax reduction in net earnings over a one-year period for foreign currency exposures on raw materials, the majority of which would occur from a weakening of the Chinese renminbi versus the U.S. dollar. Actual results may vary based on actual changes in market prices and rates.

The company is also exposed to fluctuations in prices for natural gas and electricity, as well as the cost of diesel fuel as a component of freight cost. A hypothetical 10 percent increase in our natural gas and electricity prices, without considering such pass through provisions, could result in an estimated \$11 million after-tax reduction of net earnings over a one-year period. A hypothetical 10 percent increase in diesel fuel prices could result in an estimated \$2 million

after-tax reduction of net earnings over the same period. Actual results may vary based on actual changes in market prices and rates.

Interest Rate Risk

Our objective in managing our exposure to interest rate changes is to minimize the impact of interest rate changes on earnings and cash flows and to lower our overall borrowing costs. To achieve these objectives, we use a variety of interest rate swaps, collars and options to manage our mix of floating and fixed-rate debt. Interest rate instruments held by the company at March 30, 2008, included pay-fixed interest rate swaps and interest rate collars. Pay-fixed swaps effectively convert variable rate obligations to fixed rate instruments. Collars create an upper and lower threshold within which interest rates will fluctuate.

At March 30, 2008, the company had outstanding interest rate swap agreements in Europe with notional amounts of €135 million paying fixed rates. Approximately \$3 million of a net after-tax gain associated with these contracts is included in accumulated other comprehensive earnings at March 30, 2008, of which \$1 million is expected to be recognized in the consolidated statement of earnings during the next twelve months. At March 30, 2008, the company had outstanding interest rate collars in the U.S. totaling \$150 million. The value of these contracts in accumulated other comprehensive earnings at March 30, 2008, was a loss of approximately \$0.8 million. Approximately \$1 million of net gain related to the termination or deselection of hedges is included in accumulated other comprehensive earnings at March 30, 2008. The amount recognized in 2008 earnings related to terminated hedges was insignificant.

We also use European inflation option contracts as a proxy hedge to limit the impacts from spikes in inflation against certain multi-year contracts. At March 30, 2008, the company had inflation options in Europe with notional amounts of €115 million. The company uses mark-to-market accounting for these options, and the fair value at March 30, 2008, was €0.8 million. The contracts expire within the next five years.

Based on our interest rate exposure at March 30, 2008, assumed floating rate debt levels throughout 2008 and the first three months of 2009 and the effects of derivative instruments, a 100-basis point increase in interest rates could result in an estimated \$8 million after-tax reduction in net earnings over a one-year period. Actual results may vary based on actual changes in market prices and rates and the timing of these changes.

Foreign Currency Exchange Rate Risk

Our objective in managing exposure to foreign currency fluctuations is to protect foreign cash flows and earnings from changes associated with foreign currency exchange rate changes through the use of cash flow hedges. In addition, we manage foreign earnings translation volatility through the use of various foreign currency option strategies, and the change in the fair value of those options is recorded in the company's quarterly earnings. Our foreign currency translation risk results from the European euro, British pound, Canadian dollar, Polish zloty, Chinese renminbi, Brazilian real, Argentine peso and Serbian dinar. We face currency exposures in our global operations as a result of purchasing raw materials in U.S. dollars and, to a lesser extent, in other currencies. Sales contracts are negotiated with customers to reflect cost changes and, where there is not a foreign exchange pass-through arrangement, the company uses forward and option contracts to manage foreign currency exposures. We additionally use various option strategies to manage the earnings translation of the company's European operations into U.S. dollars. Such contracts outstanding at March 30, 2008, expire within four years, and the amounts included in accumulated other comprehensive earnings related to these contracts were insignificant.

Considering the company's derivative financial instruments outstanding at March 30, 2008, and the currency exposures, a hypothetical 10 percent reduction (U.S. dollar strengthening) in foreign currency exchange rates compared to the U.S. dollar could result in an estimated \$27 million after-tax reduction in net earnings over a one-year period. This amount includes the \$14 million currency exposure discussed above in the "Commodity Price Risk" section. This hypothetical adverse change in foreign currency exchange rates would also reduce our forecasted average debt balance by \$100 million. Actual changes in market prices or rates may differ from hypothetical changes.

Common Share Repurchases

On December 3, 2007, Ball entered into a forward repurchase agreement for the purchase of 675,000 shares of its common stock. This agreement was settled for \$31 million on January 7, 2008, and the shares were delivered that day. On December 12, 2007, we also entered into an accelerated share repurchase agreement for approximately \$100 million. The agreement provided for the delivery of approximately 2 million shares, which represented 90 percent of the total estimated shares to ultimately be delivered. The \$100 million was paid on January 7, 2008, at the time the shares were delivered. The remaining shares and average price per share will be determined at the conclusion of the contract, which is expected to occur no later than June 5, 2008.

Item 4. CONTROLS AND PROCEDURES

Our chief executive officer and chief financial officer participated in management's evaluation of our disclosure controls and procedures, as defined by the Securities and Exchange Commission (SEC), as of the end of the period covered by this report and concluded that our controls and procedures were effective. During the quarter, there were no changes in the company's internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting.

FORWARD-LOOKING STATEMENT

The company has made or implied certain forward-looking statements in this report which are made as of the end of the time frame covered by this report. These forward-looking statements represent the company's goals, and results could vary materially from those expressed or implied. From time to time we also provide oral or written forward-looking statements in other materials we release to the public. As time passes, the relevance and accuracy of forward-looking statements may change. Some factors that could cause the company's actual results or outcomes to differ materially from those discussed in the forward-looking statements include, but are not limited to: fluctuation in customer and consumer growth, demand and preferences; loss of one or more major customers or changes to contracts with one or more customers; insufficient production capacity; overcapacity in foreign and domestic metal and plastic container industry production facilities and its impact on pricing; failure to achieve anticipated productivity improvements or production cost reductions, including those associated with capital expenditures such as our beverage can end project; changes in climate and weather; fruit, vegetable and fishing yields; power and natural resource costs; difficulty in obtaining supplies and energy, such as gas and electric power; availability and cost of raw materials, as well as the recent significant increases in resin, steel, aluminum and energy costs, and the ability or inability to include or pass on to customers changes in raw material costs; changes in the pricing of the company's products and services; competition in pricing and the possible decrease in, or loss of, sales resulting therefrom; insufficient or reduced cash flow; transportation costs; the number and timing of the purchases of the company's common shares; regulatory action or federal and state legislation including mandated corporate governance and financial reporting laws; the effects of the German mandatory deposit or other restrictive packaging legislation such as recycling laws; interest rates affecting our debt; labor strikes; increases and trends in various employee benefits and labor costs, including pension, medical and health care costs; rates of return projected and earned on assets and discount rates used to measure future obligations and expenses of the company's defined benefit retirement plans; boycotts; antitrust, intellectual property, consumer and other litigation; maintenance and capital expenditures; goodwill impairment; changes in generally accepted accounting principles or their interpretation; accounting changes; local economic conditions; the authorization, funding, availability and returns of contracts for the aerospace and technologies segment and the nature and continuation of those contracts and related services provided thereunder; delays, extensions and technical uncertainties, as well as schedules of performance associated with such segment contracts; international business and market risks such as the devaluation or revaluation of certain currencies and the activities of foreign subsidiaries; international business risks (including foreign exchange rates and activities of foreign subsidiaries) in Europe and particularly in developing countries such as the PRC and Brazil; changes in the foreign exchange rates of the U.S. dollar against the European euro, British pound, Polish zloty, Serbian dinar, Hong Kong dollar, Canadian dollar, Chinese renminbi, Brazilian real and Argentine peso, and in the foreign exchange rate of the European euro against the British pound, Polish zloty, Serbian dinar and Indian rupee; terrorist activity or war that disrupts the company's production or supply; regulatory action or laws including tax, environmental, health and workplace safety, including in respect of chemicals or substances used in raw materials or in the manufacturing process; technological developments and innovations; successful or unsuccessful acquisitions, joint ventures or divestitures and the integration activities associated therewith; changes to unaudited results due to statutory audits of our financial statements or management's evaluation of the company's internal controls over financial reporting; and loss contingencies related to income and other tax matters, including those arising from audits performed by U.S. and foreign tax authorities. If the company is unable to achieve its goals, then the company's actual performance could vary materially from those goals expressed or implied in the forward-looking statements. The company currently does not intend to publicly update forward-looking statements except as it deems necessary in quarterly or annual earnings reports. You are advised, however, to consult any further disclosures we make on related subjects in our 10-K, 10-Q and 8-K reports to the Securities and Exchange Commission.

PART II. OTHER INFORMATION

Item Legal Proceedings

1.

There were no events required to be reported under Item 1 for the quarter ended March 30, 2008.

Item Risk Factors

1A.

Risk factors affecting the company can be found within Item 1A of the company's annual report on Form 10-K.

Item 2. Changes in Securities

The following table summarizes the company's repurchases of its common stock during the quarter ended March 30, 2008.

(\$ in millions)	Purchases of Securities			
	Total Number of Shares Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs(b)
January 1 to February 3, 2008	2,039,533	\$ 49.05	2,039,533	11,999,198
February 4 to March 2, 2008	10,072	\$ 45.06	10,072	11,989,126
March 3 to March 30, 2008	–	–	–	11,989,126
Total	2,049,605(a)	\$ 49.03	2,049,605	

(a) Includes open market purchases and/or shares retained by the company to settle employee withholding tax liabilities.

(b) The company has an ongoing repurchase program for which shares are authorized from time to time by Ball's board of directors. On January 23, 2008, Ball's board of directors authorized the repurchase by the company of up to a total of 12 million shares of its common stock. This repurchase authorization replaced all previous authorizations.

Item Defaults Upon Senior Securities

3.

There were no events required to be reported under Item 3 for the quarter ended March 30, 2008.

Item Submission of Matters to a Vote of Security Holders

4.

There were no events required to be reported under Item 4 for the quarter ended March 30, 2008.

Item 5. Other Information

There were no events required to be reported under Item 5 for the quarter ended March 30, 2008.

Item 6. Exhibits

- 20 Subsidiary Guarantees of Debt
- 31 Certifications pursuant to Rule 13a-14(a) or Rule 15d-14(a), by R. David Hoover, Chairman of the Board, President and Chief Executive Officer of Ball Corporation and by Raymond J. Seabrook, Executive Vice President and Chief Financial Officer of Ball Corporation
- 32 Certifications pursuant to Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code, by R. David Hoover, Chairman of the Board, President and Chief Executive Officer of Ball Corporation and by Raymond J. Seabrook, Executive Vice President and Chief Financial Officer of Ball Corporation
- 99 Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995, as amended

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Ball Corporation
(Registrant)

By: /s/ Raymond J.
 Seabrook
 Raymond J. Seabrook
 Executive Vice
 President and Chief
 Financial Officer

Date: May 7, 2008

Ball Corporation and Subsidiaries
QUARTERLY REPORT ON FORM 10-Q
March 30, 2008

EXHIBIT INDEX

Description	Exhibit
Subsidiary Guarantees of Debt (Filed herewith.)	EX-20
Certifications pursuant to Rule 13a-14(a) or Rule 15d-14(a), by R. David Hoover, Chairman of the Board, President and Chief Executive Officer of Ball Corporation and by Raymond J. Seabrook, Executive Vice President and Chief Financial Officer of Ball Corporation (Filed herewith.)	EX-31
Certifications pursuant to Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code, by R. David Hoover, Chairman of the Board, President and Chief Executive Officer of Ball Corporation and by Raymond J. Seabrook, Executive Vice President and Chief Financial Officer of Ball Corporation (Furnished herewith.)	EX-32
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995, as amended (Filed herewith.)	EX-99

